Table 1.
Demographic and clinical data.
| Variable | Category | Number of Patients (%) | Mean |
|---|---|---|---|
| Gender | Female | 7 (36.8%) | |
| Male | 12 (63.2%) | ||
| Age at surgery | 48.9 years (range 17–81) | ||
| Charlson Comorbidity Index | 3.7 (range 2–7) | ||
| Pain | Yes | 19 (100%) | |
| No | 0 | ||
| Type of tumor | Chordoma | 11 (57.9%) | |
| Chondrosarcoma | 2 (10.5%) | ||
| Spindle cell sarcoma | 1 (5.3%) | ||
| Osteoid osteoma | 1 (5.3%) | ||
| ABC | 1 (5.3%) | ||
| Malignant myofibroblastic tumor of bone | 1 (5.3%) | ||
| Metastases | 2 (10.5%) | ||
| Previous treatments | Yes | 3 (1 incisional biopsy; 1 radiation therapy; 1 chemotherapy) | |
| No | 16 | ||
| Preoperative SAE | Yes | 16 (84.2%) | |
| No | 3 (15.7%) | ||
| Type of surgery | High sacral partial resection (above the S3 segment) | 4 (21.1%) | |
| Low sacral resection (at or below the S3 segment) | 15 (78.9%) | ||
| Surgical margin | R0 | 12 (63.2%) | |
| R1 | 7 (36.8%) | ||
| Surgical approach | Posterior | 14 (73.7%) | |
| Anterior | 1 (5.3%) | ||
| Double (posterior + anterior) | 4 (21.1%) | ||
| Neurological sacrifice | Yes | 5 (26.3%) | |
| No | 14 (73.7%) | ||
| Adverse events | Postoperative | 12 (63.2%) | |
| 5 wound dehiscence | |||
| 7 minor complications | |||
| Length of stay | 15.7 days | ||
| Local recurrence | Yes | 5 (26.3%) | |
| No | 14 (73.7%) | ||
| Metastases/other localizations | Yes | 4 (21.1%) | |
| No | 15 (78.9%) | ||
| Follow-up | 49.1 months (range 13–127) | ||
| Adjuvant treatments | RT | 5 (26.3%) | |
| CHT | 4 (21.1%) |